What is Alkermes?
Alkermes plc operates at the intersection of neuroscience and patient-inspired science, developing and commercializing innovative medicines for conditions such as addiction, schizophrenia, bipolar disorder, and opioid dependence. Headquartered in Dublin, Ireland, the company leverages its deep expertise in scientific research, clinical development, and specialized commercial infrastructure to deliver both marketed therapies and investigational candidates. Alkermes aims to significantly improve the management of chronic neurological and mental health conditions, addressing critical gaps in current treatment paradigms.
How much funding has Alkermes raised?
Alkermes has raised a total of $251.2M across 2 funding rounds:
Stock Offering
$1.2M
Share Placement
$250M
Stock Issuance/Offering (1991): $1.2M, investors not publicly disclosed
Share Placement (2014): $250M led by Invesco
Key Investors in Alkermes
Invesco
Invesco is a global investment management firm providing a wide range of investment services to institutional and retail clients. Their broad investment scope suggests a strategic interest in established companies with significant market potential, aligning with Alkermes' biopharmaceutical focus.
What's next for Alkermes?
With a history of substantial financial backing, Alkermes is strategically positioned for continued growth and innovation in the biopharmaceutical sector. The recent enterprise-level funding, coupled with its established pipeline and commercial capabilities, suggests a focus on expanding its therapeutic offerings and market reach. Future endeavors will likely involve advancing late-stage clinical candidates, potentially pursuing new drug discoveries, and further solidifying its presence in the complex psychiatric and neurological disorder landscape. The company's commitment to addressing serious unmet medical needs underscores its long-term strategic vision.
See full Alkermes company page
